Document 1130 DOCN M94A1130 TI ComPACT 1: a randomized, controlled trial of immediate vs. deferred antiretroviral therapy in asymptomatic HIV infected individuals. DT 9412 AU Mitchell T; Abrams D; Smith RP; Meier P; Peto R; University of California, San Francisco. SO Int Conf AIDS. 1994 Aug 7-12;10(2):202 (abstract no. PB0821). Unique Identifier : AIDSLINE ICA10/94371445 AB It is unclear from the currently available evidence whether a policy of immediate or deferred intervention with antiretroviral therapy would produce the best chances of increased survival in asymptomatic HIV infection. In order to reliably assess which policy is best, a pilot study for a large, simple trial is under way. Primary care providers in New York, San Francisco, Los Angeles and Washington DC are able to randomize their patients to a policy of immediate or Deferred antiretroviral therapy through a toll free call. Annual follow up includes the participant's most recent CD4 cell count, whether they are taking antiretroviral therapy, and the date when the person was last known to be alive. Updated information on the rate of enrollment, the demographics and compliance of enrolled patients will be presented. Of the patients for whom follow up data are available, 50% have CD4 cell counts above 500 (range 70-1014). Ages range from 21-60. 45% are people of color, 6% are women. If the pilot study is successful, a large scale randomization is planned, within which at least 10,000 asymptomatic HIV infected people would be invited to participate. DE Adult Antiviral Agents/*ADMINISTRATION & DOSAGE Female Human HIV Infections/*DRUG THERAPY/IMMUNOLOGY Leukocyte Count Male Middle Age Pilot Projects T4 Lymphocytes CLINICAL TRIAL MEETING ABSTRACT RANDOMIZED CONTROLLED TRIAL SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).